CN Patent

CN106928320B — 一种合成Etelcalcetide的方法

Assigned to Hybio Pharmaceutical Co Ltd · Expires 2021-01-15 · 5y expired

What this patent protects

本发明涉及医药合成领域，公开了一种合成Etelcalcetide的方法。本发明所述方法采用固相合成的策略，先合成Etelcalcetide主链肽树脂，再脱除肽链中Cys的侧链保护基，而后以2,2’‑二硫二吡啶活化肽树脂上Cys侧链的巯基并与L‑Cys构建二硫键，经裂解得到Etelcalcetide粗肽，整个过程不用经过多步纯化，所获粗肽收率和纯度较高，且纯化后精肽的总收率大幅提高。

USPTO Abstract

本发明涉及医药合成领域，公开了一种合成Etelcalcetide的方法。本发明所述方法采用固相合成的策略，先合成Etelcalcetide主链肽树脂，再脱除肽链中Cys的侧链保护基，而后以2,2’‑二硫二吡啶活化肽树脂上Cys侧链的巯基并与L‑Cys构建二硫键，经裂解得到Etelcalcetide粗肽，整个过程不用经过多步纯化，所获粗肽收率和纯度较高，且纯化后精肽的总收率大幅提高。

Drugs covered by this patent

Patent Metadata

Patent number
CN106928320B
Jurisdiction
CN
Classification
—
Expires
2021-01-15
Drug substance claim
No
Drug product claim
No
Assignee
Hybio Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.